Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 20% Improvement Relative Risk Improvement at day 28 35% c19early.org/s Garibaldi et al. Remdesivir for COVID-19 LATE Is late treatment with remdesivir beneficial for COVID-19? Retrospective 606 patients in the USA Greater improvement with remdesivir (p=0.000015) Garibaldi et al., medRxiv, doi:10.1101/2020.11.19.20234153 Favors remdesivir Favors control
Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19
Garibaldi et al., medRxiv, doi:10.1101/2020.11.19.20234153 (Preprint)
Garibaldi et al., Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19, medRxiv, doi:10.1101/2020.11.19.20234153 (Preprint)
Nov 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 303 remdesivir patients and 303 matched controls showing significantly faster clinical improvement, and lower (but not statistically significant) mortality.
[Gérard, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 20.0% lower, HR 0.80, p = 0.44, treatment 23 of 303 (7.6%), control 45 of 303 (14.9%), adjusted per study.
risk of no improvement at day 28, 35.0% better, RR 0.65, p < 0.001, treatment 52 of 303 (17.2%), control 80 of 303 (26.4%), NNT 11, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Garibaldi et al., 20 Nov 2020, retrospective, USA, preprint, 10 authors.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.11.19.20234153; this version posted November 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Title: Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19 Brian T. Garibaldi MD MEHP1*, Kunbo Wang MS2*, Matthew L. Robinson MD3, Scott L. Zeger PhD4, Karen Bandeen Roche PhD4, Mei-Cheng Wang PhD4, G. Caleb Alexander MD5, Amita Gupta MD3, Robert Bollinger MD MPH3, Yanxun Xu PhD2,6 1 Division of Pulmonary and Critical Care, Johns Hopkins University School of Medicine, Baltimore, MD 2 Department of Applied Mathematics and Statistics, Johns Hopkins University, Baltimore, MD USA 3 Division of Infectious Disease, Johns Hopkins University School of Medicine, Baltimore, MD USA 4 Division of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA 5 Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA 6 Division of Biostatistics and Bioinformatics at The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD USA * Dr. Garibaldi and Mr. Wang contributed equally to this article. * Dr. Garibaldi and Mr. Wang contributed equally to this article. BTG, KW, YX contributed to the conception and design of the work, the acquisition, analysis, and interpretation of data MR, SZ, KBR, MCW, CA, AG, RB contributed to the conception and design of the work and interpretation of the data. All authors contributed to the drafting and revising of the manuscript for important intellectual content, give final approval of the version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Corresponding Author Brian T. Garibaldi, MD MEHP Division of Pulmonary and Critical Care Medicine Johns Hopkins University School of Medicine 1830 East Monument Street Baltimore, MD 21205 (443) 804-8286 Bgariba1@jhmi.edu Funding and Support: JH-CROWN received funding from Hopkins inHealth, the Johns Hopkins Precision Medicine Program. BTG, KW, MR, AG and YX received funding from the COVID-19 Administrative Supplement for the HHS Region 3 Treatment Center from the Office of the Assistant Secretary for Preparedness and Response. 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.11.19.20234153; this version posted November 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. ABSTRACT Rationale: Remdesivir and dexamethasone reduced the severity of COVID-19 in clinical trials. However, their individual or combined effectiveness in clinical practice remains unknown. Objectives: To examine the effectiveness of remdesivir with or without dexamethasone. Methods: We conducted a multicenter, retrospective cohort study between March 4 and August 29, 2020. Eligible COVID cases were hospitalized patients treated with..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit